Leukemia Stem Cell Markers for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial seeks a less invasive method to predict the effectiveness of treatments for acute myeloid leukemia (AML). Instead of bone marrow biopsies, the study examines specific blood markers, CLL1 and CD45RA. These markers may enable doctors to adjust treatments more quickly and effectively. Individuals with AML who can receive treatment at the research center and have elevated levels of these markers might be suitable candidates for this trial. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in AML care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that tracking CLL1 and CD45RA positive LSC in peripheral blood is safe for predicting therapeutic outcomes in AML?
A study focused on treatments targeting CLL1 in acute myeloid leukemia (AML) showed that these therapies are generally well-tolerated. Patients experienced good safety and effectiveness in managing challenging cases of AML. However, limited information exists on the long-term safety of CLL1-targeted treatments, necessitating further research to confirm these results over time.
Regarding CD45RA, the safety information lacks specific details about its immediate risks or side effects. This indicates insufficient detailed safety information, suggesting that CD45RA is still under study for its safety.
In summary, while CLL1 shows promise with a good safety record in early studies, the limited long-term data should be considered. CD45RA's safety details are not well-documented, and ongoing studies might provide more insights. Participants should consider these factors when deciding to join a trial.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on identifying specific markers of leukemia stem cells, namely CLL1 and CD45RA, in Acute Myeloid Leukemia (AML). Unlike traditional treatments that target rapidly dividing cells, this approach aims to pinpoint and target the root of the disease by focusing on leukemia stem cells. This could potentially lead to more effective and lasting treatments, reducing the likelihood of relapse. By understanding and targeting these markers, there's hope for developing therapies that are more precise and have fewer side effects compared to conventional chemotherapy.
What evidence suggests that tracking CLL1 and CD45RA positive LSC in peripheral blood is effective for predicting therapeutic outcomes in AML?
Research has shown that tracking leukemia stem cells (LSCs) using markers like CLL1 and CD45RA can predict treatment effectiveness for acute myeloid leukemia (AML). Studies have found that changes in LSC numbers with these markers closely link to patient responses to therapy. CLL1 and CD45RA appear on many leukemia cells in AML patients, making them reliable indicators of disease progression. Early findings suggest that checking these markers in the blood, rather than performing invasive bone marrow biopsies, could offer a faster and less painful way to assess treatment effectiveness. This method may help customize treatments and reduce side effects.678910
Who Is on the Research Team?
Suhu Liu, MD PhD
Principal Investigator
Stony Brook Medicine
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment for acute myeloid leukemia while tracking leukemia stem cells in peripheral blood
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CD45RA
- CLL1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Suhu Liu
Lead Sponsor
Citations
1.
ashpublications.org
ashpublications.org/blood/article/142/Supplement%201/5992/506180/Use-of-CLL1-and-CD45RA-As-Biomarkers-for-LeukemiaUse of CLL1 and CD45RA As Biomarkers for Leukemia Stem ...
In this study, we focus on newly diagnosed AML patients undergoing induction therapy to determine whether information gained from LSC subset ...
2.
clinicaltrials.gov
clinicaltrials.gov/study/NCT06297551?locStr=United+States&country=United+States&aggFilters=status%3AAcute Myeloid Leukemia and Markers of Leukemia Stem Cells ...
There are three types of violations: Failure to submit required clinical trial information; Submission of false or misleading clinical trial information ...
Acute Myeloid Leukemia: Diagnosis and Evaluation by ...
Flow cytometry offers rapid and sensitive immunophenotyping through a multiparametric approach and is a pivotal laboratory tool for the classification of AML.
Use of CLL1 and CD45RA As Biomarkers for Leukemia ...
In this study, we focus on newly diagnosed AML patients undergoing induction therapy to determine whether information gained from LSC subset ...
Potent anti-tumor activity of CD45RA-targeting Hm3A4- ...
CD45RA is expressed on leukemic cells in most AML patients. CD45RA has been used as a marker to specifically identify LSC and HSC and improve LSC quantification ...
SAFETY DATA SHEET
Unknown acute toxicity. 0 % of the mixture consists of ingredient(s) of unknown toxicity. 0 % of the mixture consists of ingredient(s) of ...
Safety Data Sheets
Safety Data Sheets ; Anti-Human CD45RA (HI100)-169Tm?25 Tests. CATEGORY: Cytometry. Part Number: 3169008C ; Anti-Human CD45RA (HI100)-170Er?100 Tests. CATEGORY: ...
8.
bdbiosciences.com
bdbiosciences.com/content/dam/bdb/product_assets/product_pdf/singcolorpureantibody/fitc/pdf_0/23-7066.pdfBD CD45RA (L48)
Go to regdocs.bd.com/regdocs/sdsSearch to download the Safety Data Sheet. Storage and Handling. • Store the reagent at 2–8 °C. • Reagent in unopened vials is ...
APC anti-human CD45RA
Refer to the reagent safety data sheet. This antibody contains sodium azide. Follow federal, state and local regulations to dispose of this reagent. Sodium ...
97321 CD45RA (HI100) Mouse mAb (APC Conjugate)
97321 CD45RA (HI100) Mouse mAb (APC Conjugate). Supplemental hazard statement(s). EUH210 - Safety data sheet available on request. 2.3. Other hazards. For the ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.